Delivery of steroids into the eye for the treatment of macular edema

Expert Opinion on Drug Delivery

Volumn 13, Issue 8, 2016, Pages 1083-1091

  Hadayer, Amir ^a   Schaal, Shlomit ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

drug delivery; Iluvien; inflammation; injection; Intraocular; intravitreal; Kenalog; macular edema; Ozurdex; Retisert; steroids; sustained release

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE; STEROID; GLUCOCORTICOID;

BIODEGRADABLE IMPLANT; DRUG IMPLANT; HUMAN; INTRAVITREAL IMPLANT; IONTOPHORETIC DELIVERY DEVICE; MACULAR EDEMA; MICROINJECTOR; MULTICENTER STUDY (TOPIC); NONHUMAN; OPHTHALMIC DRUG DELIVERY DEVICE; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLOW RELEASE FORMULATION; STEROID THERAPY; SYSTEMIC THERAPY;

GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA;

EID: 84978881190     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1182488     Document Type: Review

References (33)

1. M.Lloyd Philip Showalter Hench, 1896–1965. Rheumatology (Oxford). 2002;41:582–584.• An interesting historical review on Philip Showalter Hench and the discovery of corticosteroids and their clinical use.
2. P.J.Barnes. How corticosteroids control inflammation: quintiles prize lecture 2005. Br J Pharmacol. 2006;148:245–254.
3. A.E.Coutinho, K.E.Chapman. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.• A mini review of steroid penetration in the eye using different steroid compounds and methods.
4. M.Zierhut, C.Pavesio, S.Ohno, et al. Intraocular inflammation. New York (NY): Springer; 2016.
5. O.Weijtens, R.C.Schoemaker, F.P.Romijn, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109:1887–1891.
6. O.Weijtens, E.J.Feron, R.C.Schoemaker, et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am J Ophthalmol. 1999;128:192–197.
7. C.N.McGhee, D.G.Watson, J.M.Midgley, et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye (Lond). 1990;4:526–530.
8. C.N.McGhee. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76:681–684.
9. W.Stringer, R.Bryant. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;4:1119–1124.
10. C.S.Foster, R.Davanzo, T.E.Flynn, et al. Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26:475–483.
11. J.Ohm. Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Graefe Arch Klin Ophthalmol. 1911;79:442–450.
12. L.Von Sallmann, K.Meyer, J.Di Grandi. Experimental study on penicillin treatment of ectogenous infection of vitreous. Arch Ophthalmol. 1944;32:179–189.
13. R.Machemer, G.Sugita, Y.Tano. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171–180.
14. P.M.Beer, S.J.Bakri, R.J.Singh, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–686.
15. M.J.Elman, L.P.Aiello, R.W.Beck, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.e35.
16. I.U.Scott, M.S.Ip, P.C.VanVeldhuisen, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115–1128
17. M.S.Ip, I.U.Scott, P.C.VanVeldhuisen, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101–1114.
18. B.L.VanderBeek, S.G.Bonaffini, L.Ma. Association of compounded bevacizumab with postinjection endophthalmitis. JAMA Ophthalmol. 2015;133:1159–1164.
19. B.L.VanderBeek, S.G.Bonaffini, L.Ma. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122:2311–2315.
20. N.M.Bressler, A.R.Edwards, R.W.Beck, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol. 2009;127:1566–1571.
21. R.W.Beck, A.R.Edwards, L.P.Aiello, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–251.
22. J.A.Haller, F.Bandello, R.BelfortJr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.
23. J.A.Haller, B.D.Kuppermann, M.S.Blumenkranz, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–296.
24. C.Lowder, R.BelfortJr, S.Lightman, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–553.
25. J.Cunha-Vaz, P.Ashton, R.Iezzi, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121:1892–1903.
26. P.A.Campochiaro, D.M.Brown, A.Pearson, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–2132.
27. G.J.Jaffe, D.Martin, D.Callanan, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027.
28. S.R.Patel, D.E.Berezovsky, B.E.McCarey, et al. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the EyeMicroneedle use for targeted drug delivery. Invest Ophthalmol Vis Sci. 2012;53:4433–4441.
29. B.C.Gilger, E.M.Abarca, J.H.Salmon, et al. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedlestriamcinolone in the suprachoroidal space. Invest Ophthalmol Vis Sci. 2013;54:2483–2492.
30. N.Kuno, S.Fujii. Ocular drug delivery systems for the posterior segment: a review. Retina Today. 2012;5:54–59.
31. A.E.Cohen, C.Assang, M.A.Patane, et al. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology. 2012;119:66–73.
32. J.I.Lim, A.E.Fung, M.Wieland, et al. Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion. Ophthalmology. 2011;118:1416–1422.
33. A.Ozkok, O.A.Saleh, D.K.Sigford, et al. THE OMAR STUDY: comparison of Ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina. 2015;35:1393–1400.